Brain magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy reveals regional reductions in cerebral gray matter [PDF]
BMC Neuroscience, 2023 Background Duchenne muscular dystrophy is a X-linked disease characterized by severe and progressive muscle weakness, alongside cognitive impairment and a range of neurobehavioral disorders secondary to brain dystrophin deficiency.
Abbe H. Crawford +3 more
doaj +3 more sources
Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy [PDF]
Disease Models & Mechanisms, 2022 Duchenne muscular dystrophy (DMD), a fatal musculoskeletal disease, is associated with neurodevelopmental disorders and cognitive impairment caused by brain dystrophin deficiency.
Abbe H. Crawford +5 more
doaj +4 more sources
Longitudinal assessment of skeletal muscle functional mechanics in the DE50-MD dog model of Duchenne muscular dystrophy [PDF]
Disease Models & Mechanisms, 2023 Dominique O. Riddell +6 more
doaj +4 more sources
Serum inflammatory cytokines as disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy [PDF]
Disease Models & Mechanisms, 2022 Dominique O. Riddell +5 more
doaj +4 more sources
Long-term, age-associated activity quantification in the DE50-MD dog model of Duchenne muscular dystrophy [PDF]
Disease Models & MechanismsKamila Karimjee +6 more
doaj +4 more sources
The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophy [version 1; peer review: 2 approved] [PDF]
Wellcome Open Research, 2022 Background: Animal models of Duchenne muscular dystrophy (DMD) are essential to study disease progression and assess efficacy of therapeutic intervention, however dystrophic mice fail to display a clinically relevant phenotype, limiting translational ...
Claire Massey +8 more
doaj +2 more sources
Longitudinal assessment of blood-borne musculoskeletal disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy [version 2; peer review: 2 approved] [PDF]
Wellcome Open Research, 2022 Background: Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by mutations in the dystrophin gene. Due to their phenotypic similarity to human patients, large animal models are invaluable tools for pre-clinical trials.
John C. W. Hildyard +4 more
doaj +2 more sources
Identification of reference microRNAs in skeletal muscle of a canine model of Duchenne muscular dystrophy [version 2; peer review: 2 approved] [PDF]
Wellcome Open ResearchBackground Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by mutations in the dystrophin gene. DE50-MD dogs are an animal model of DMD used as a final translational model for evaluation of promising treatments.
Richard J. Piercy +4 more
doaj +2 more sources
Evaluation of a six-minute walk test in the DE50-MD canine model of Duchenne muscular dystrophy and its effect on blood-borne biomarkers [version 2; peer review: 1 approved, 2 approved with reservations] [PDF]
Wellcome Open ResearchBackground Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by mutations in the dystrophin gene resulting in cycles of muscle degeneration, inflammation and regeneration. The 6-minute walk test (6MWT) is a key functional outcome
Richard Piercy +4 more
doaj +2 more sources
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC [PDF]
npj Precision OncologyChemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical
Masayuki Shirasawa +10 more
doaj +2 more sources